Alzheimer's disease (AD), most common form of dementia, is thought to affect 10 percent of adults over 65 years old, with women at greater risk. One theory is that lower levels of estrogen may increase risks of dementia in postmenopausal women. Numerous studies suggest that women taking HRT have less risk of dementia.

However, vast majority of studies have failed to separate use of estrogen alone and estrogen plus progestin and these latest results appear to contradict earlier findings. This raises question as to which component of drug is responsible for side-effects of Prempro, such as increasing risk of dementia. This debate is being played out in courtrooms handling litigation involving side-effects of Prempro.

Prempro has also previously come under fire following termination of WHI long-term study because of increased ovarian cancer risks, heart attacks, and strokes. Further investigation into association of estrogen therapies and dementia is now warranted.

Monheit Law is investigating Prempro Cancer cases for long term users of Prempro who have developed either breast or ovarian cancer.

See: http://www.monheit.com/prempro/responsible.shtml

Monheit Law is investigating Prempro Cancer cases for long term users of Prempro who have developed either breast or ovarian cancer.

See: http://www.monheit.com/prempro/being_done.shtml